| CAS NO: | 34140-59-5 |
| 包装 | 价格(元) |
| Free Sample (0.1-0.5mg) | 电议 |
| 10mM (in 1mL DMSO) | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| 50g | 电议 |
| Cas No. | 34140-59-5 |
| 别名 | 马来酸曲美布汀 |
| Canonical SMILES | O=C(O)/C=C\C(O)=O.O=C(OCC(C1=CC=CC=C1)(N(C)C)CC)C2=CC(OC)=C(OC)C(OC)=C2 |
| 分子式 | C26H33NO9 |
| 分子量 | 503.54 |
| 溶解度 | DMSO: 100 mg/mL (198.59 mM); Water: 25 mg/mL (49.65 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Trimebutine maleate is a drug with antimuscarinic and weak mu opioid agonist effects.Target: Opioid ReceptorTrimebutine is an agonist of peripheral mu, kappa and delta opiate receptors, used as spasmolytic agent for treatment of both acute and chronic abdominal pain [1]. The major product from drug metabolism of trimebutine in human beings is nor-trimebutine, which comes from removal of one of the methyl groups attached to nitrogen. Trimebutine exerts its effects in part due to causing a premature activation of phase III of the migrating motor complex in the digestive tract [2, 3]. [1]. Kaneto, H., M. Takahashi, and J. Watanabe, The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies. J Pharmacobiodyn, 1990. 13(7): p. 448-53. [2]. Roman, F.J., et al., Pharmacological properties of trimebutine and N-monodesmethyltrimebutine. J Pharmacol Exp Ther, 1999. 289(3): p. 1391-7. [3]. Hiyama, T., et al., Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract. J Gastroenterol Hepatol, 2009. 24(4): p. 537-46. |
m.cnreagent.com